marketshareAI

AstraZeneca

AZNHealthcare
10,134.00GBX
-3.52%
Market Cap
165.87B
Volume
126
0% of avg
P/E Ratio
14.04
EPS (TTM)
7.22
Beta
0.18
Day Range
0.00p - 0.00p
52 Week Range
0.00p10,134.00p13,388.00p
10,134.00p

Upcoming Events

May 9, 2025
RNS announcement on Imfinzi trial results
High Impact Event
June 2025
EU regulatory decision on Calquence for 1st-line mantle cell lymphoma
High Impact Event
June 2025
Regulatory submissions for Truqap in mHSPC
High Impact Event
Q2 2025
Acquisition of EsoBiotec expected to close
High Impact Event
29 July 2025
Announcement of H1 and Q2 2025 results
High Impact Event
6 November 2025
Announcement of 9M and Q3 2025 results
High Impact Event
Q4 2025
Presentation of 52-week data from CALYPSO trial
High Impact Event
2026
Potential regulatory submission for eneboparatide
High Impact Event
AZN
NEUTRAL

AstraZeneca's Imfinzi shows positive results in early bladder cancer trial

The biopharmaceutical company reported positive results from a late-stage trial evaluating its cancer drug Imfinzi in patients with early-stage bladder cancer.

AZN
NEUTRAL

AstraZeneca's Enhertu shows improved pCR in early-stage HER2-positive breast cancer

The biopharmaceutical company reported positive results from a Phase III trial of its HER2-directed antibody drug conjugate Enhertu in patients with high-risk, early-stage HER2-positive breast cancer.

AZN
NEUTRAL

AstraZeneca's Calquence Combination Approved in EU for First-Line Mantle Cell Lymphoma

The biopharmaceutical company has received European approval for its Calquence combination therapy to treat a rare form of lymphoma.

AZN
NEUTRAL

AstraZeneca's Breztri Aerosphere meets primary endpoints in asthma trials

The biopharmaceutical company announced that its triple-combination therapy Breztri Aerosphere met primary endpoints in two Phase III asthma trials, demonstrating potential to improve treatment for patients with uncontrolled asthma.

AZN
NEUTRAL

AstraZeneca Announces Director Share Purchase

The pharmaceutical company has announced that a Non-Executive Director has purchased shares in the business.

AZN
NEUTRAL

AstraZeneca's Calquence Combination Regimens Recommended for EU Approval in Previously Untreated CLL

The healthcare company's Calquence combination regimens have been recommended for approval in the EU for the treatment of previously untreated chronic lymphocytic leukemia.

AZN
NEUTRAL

AstraZeneca discontinues CAPItello-280 Phase III trial of Truqap in metastatic prostate cancer

The pharmaceutical company has discontinued a Phase III trial evaluating a cancer drug in metastatic prostate cancer.

AZN
GOOD

AstraZeneca Reports Strong Q1 2025 Results, Driven by Oncology and BioPharmaceuticals

The biopharmaceutical company reported strong Q1 2025 results, with double-digit revenue growth and positive pipeline developments. The company maintains a solid financial position despite an increase in net debt.

AZN
NEUTRAL

AstraZeneca reports positive results from DESTINY-Breast09 trial of Enhertu combination in HER2-positive metastatic breast cancer

The biopharmaceutical company reported positive results from a Phase III trial of its HER2-targeted drug Enhertu in combination with pertuzumab for first-line treatment of HER2-positive metastatic breast cancer.

AZN
NEUTRAL

AstraZeneca's Imfinzi approved in EU for resectable lung cancer

The healthcare company announced that its cancer drug Imfinzi has been approved in the EU for treating a certain type of lung cancer.